The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence
| Autor: | Frank T. Leone, Grace Crawford, Annie R. Peng, Robert A. Schnoll, Rachel F. Tyndale, Nancy C. Jao, Jessica Weisbrot, Brian Hitsman, Ravi Kalhan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Research paper lcsh:Social pathology. Social and public welfare. Criminology medicine.medical_treatment Population lcsh:BF1-990 Smoking cessation lcsh:HV1-9960 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Gastrointestinal cancer Varenicline education education.field_of_study Receiver operating characteristic business.industry Head and neck cancer Area under the curve Cancer medicine.disease Psychiatry and Mental health lcsh:Psychology chemistry Adherence 030220 oncology & carcinogenesis business Tobacco dependence |
| Zdroj: | Addictive Behaviors Reports, Vol 8, Iss, Pp 46-50 (2018) Addictive Behaviors Reports |
| ISSN: | 2352-8532 |
| Popis: | Introduction The degree to which smokers quit successfully with varenicline is strongly associated with their adherence to the medication regimen. Thus, measuring varenicline adherence to identify smokers needing additional intervention is a priority. Few studies, however, have examined the validity of self-reported varenicline adherence, using a biological assessment of adherence as a reference. No study has examined this issue among cancer patients trying to quit smoking, who may show unique patterns of adherence given their medical comorbidity. Methods This study used data from 76 cancer patients who received varenicline and provided self-reported varenicline adherence data (pill count) and a blood sample to determine varenicline metabolites 4 weeks after initiating varenicline. Results Receiver operating characteristic (ROC) curve analyses of plasma varenicline levels showed that 4 ng/ml was the optimal cut-point for differentiating adherence with significant (p's Highlights • First study of the validity of self-reported varenicline use among cancer patients • Identified cut-point for varenicline plasma adherence • Supports the validity of short-term self-reported varenicline adherence • Cancer-related variables influence varenicline adherence • Varenicline adherence may be higher among cancer patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|